A study evaluating clinical outcomes of patients treated with osimertinib in patients previously treated with EGF816 for assessing cross resistance between EGF816 and osimertinib.

Trial Profile

A study evaluating clinical outcomes of patients treated with osimertinib in patients previously treated with EGF816 for assessing cross resistance between EGF816 and osimertinib.

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 13 Jun 2017

At a glance

  • Drugs Osimertinib (Primary)
  • Indications Adenocarcinoma; Non-small cell lung cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 13 Jun 2017 New trial record
    • 06 Jun 2017 Results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top